Valuation : OLIPASS Corporation

Market Cap 2.65TCr 1.97Cr 1.7Cr 1.59Cr 1.46Cr 2.73Cr 186Cr 2.73Cr 19Cr 7.31Cr 95Cr 7.4Cr 7.24Cr 307.43Cr P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 2.03TCr 1.51Cr 1.3Cr 1.22Cr 1.12Cr 2.09Cr 142.57Cr 2.09Cr 14Cr 5.61Cr 73Cr 5.67Cr 5.55Cr 235.65Cr EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
34,500
5 years 1,568
Extreme 1568
1,35,500
10 years 1,568
Extreme 1568
2,40,666.67
Manager TitleAgeSince
Chief Executive Officer 54 22/05/2025
Corporate Officer/Principal 34 28/11/2024
Comptroller/Controller/Auditor 67 31/03/2025
Director TitleAgeSince
Director/Board Member 54 28/11/2024
Director/Board Member 34 28/11/2024
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-92.46% 99.99L
-1.79%-2.27%+43.23%+88.96% 6.8TCr
-2.06%-0.18%+39.67%+86.44% 6.49TCr
-0.31%+6.54%-12.96%+378.92% 2.76TCr
+0.86%+1.65%-7.74%-14.95% 2.61TCr
-3.00%-2.90%+33.13%+12.54% 2.57TCr
-1.46%+0.42%+23.61%-18.61% 2.01TCr
-2.96%-15.21%+216.20%+368.10% 1.72TCr
-1.49%-4.88%-6.60%+531.89% 1.49TCr
-0.20%+8.37%+55.78%+164.98% 1.46TCr
Average -2.63%-4.36%+38.43%+150.58% 2.79TCr
Weighted average by Cap. -1.52%+0.17%+38.37%+137.34%

Financials

2021 2022
Net sales 85Cr 6L 5L 5L 5L 9L 5.97Cr 9L 60.51L 23.48L 3.06Cr 23.75L 23.23L 9.87Cr 229.6Cr 17.05L 14.67L 13.8L 12.61L 23.59L 16Cr 23.65L 1.63Cr 63.29L 8.26Cr 64.02L 62.62L 27Cr
Net income -2.51TCr -1.87Cr -1.61Cr -1.51Cr -1.38Cr -2.58Cr -176.21Cr -2.59Cr -18Cr -6.93Cr -90Cr -7.01Cr -6.86Cr -291.26Cr -2.42TCr -1.79Cr -1.54Cr -1.45Cr -1.33Cr -2.48Cr -169.43Cr -2.49Cr -17Cr -6.66Cr -87Cr -6.74Cr -6.59Cr -280.05Cr
Net Debt -1.83TCr -1.36Cr -1.17Cr -1.1Cr -1Cr -1.88Cr -128.23Cr -1.88Cr -13Cr -5.04Cr -66Cr -5.1Cr -4.99Cr -211.95Cr -619.5Cr -46L -39.58L -37.24L -34.02L -63.64L -43Cr -63.82L -4.4Cr -1.71Cr -22Cr -1.73Cr -1.69Cr -72Cr
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
-
  1. Stock Market
  2. Stocks
  3. A244460 Stock